REGiMMUNE

Executive Summary

REGiMMUNE is a clinical-stage biotechnology company based in Taipei, Taiwan, focused on developing innovative Treg-modulating immunotherapies to treat autoimmune diseases, transplant rejection, and cancer. The company's proprietary platform leverages liposomal alpha-galactosylceramide (α-GalCer) analogs designed to expand regulatory T cells (Tregs) in a targeted manner, offering potential for immune tolerance induction in autoimmune and transplantation settings. Concurrently, REGiMMUNE is developing antibodies that selectively deplete activated Tregs within the tumor microenvironment, aiming to enhance anti-tumor immunity. This dual approach positions the company at the forefront of immunomodulation, addressing both ends of the immune spectrum—suppression and activation—through a single integrated platform. Currently, REGiMMUNE is advancing its lead candidate through Phase 2 clinical studies, with initial data anticipated in the near term. The platform's versatility has generated interest from both academic and industry partners, and the company is actively exploring collaborations to expand its pipeline. The global autoimmune disease and immuno-oncology markets represent substantial opportunities, and REGiMMUNE's novel mechanism of action could differentiate it from existing therapies. However, as a private company in early-stage development, execution risk remains significant. The preclinical and clinical data generated so far will be critical in validating the platform's potential and securing further financing or partnerships.

Upcoming Catalysts (preview)

• Q4 2026Interim Phase 2 data readout for lead Treg-expanding candidate in autoimmune disease55% success
• H1 2027IND filing for Treg-depleting antibody in oncology60% success
• TBDPotential partnership or licensing deal for platform technology50% success